CEO of Novonesis (merged Chr. Hansen and Novozymes), previously spent 25 years at DSM in chemicals. Chemical engineer with MBA, Spanish/Catalan leading a Danish-headquartered global bio-solutions company. Focused on replacing fossil-based chemicals with nature-based alternatives via enzymes and microbes.
no scored calls yet — needs a stated position or a categorical verdict, with a matured window vs SPY
Novonesis addresses a $60B biosolutions market and $1T specialty chemicals market, growing high-single digits by outpacing end-markets 2-4x, with 37% EBITDA margins driven by pricing discipline (1-2% annual price contribution), 10% revenue R&D spend, 100K+ strain library, and AI-accelerated protein design; new frontiers include carbon capture, plastic recycling, and specialized proteins.